Background The release of pro-inflammatory cytokines, resulting in cytokine storm
syndrome, contributes to the morbidity and mortality associated with COVID-19 disease. This …

Patients with coronavirus disease 2019 (COVID‐19) may develop severe respiratory
distress, thought to be mediated by cytokine release. Elevated proinflammatory markers …

Background Tocilizumab, an inhibitor of the interleukin-6 receptor, may decrease the
inflammatory response and control the symptoms of severe coronavirus disease 2019 …

Background Current evidence suggests an important role of the interleukin‐6 (IL‐6) pathway
in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐related cytokine …

COVID-19 pandemic has become a global concern. Cytokine release syndrome (CRS)
complicates acute respiratory distress syndrome (ARDS) and causes multi-organ failure …

Background Due to the lack of proven therapies, we evaluated the effects of early
administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab …

Abstract Severe COVID-19 (coronavirus disease 2019) is associated with elevated
inflammatory markers, consistent with cytokine release syndrome (CRS). Tocilizumab is an …

Abstract Coronavirus disease 2019 (COVID‐19) can lead to a massive cytokine release. The
use of the anti‐interleukin‐6 receptor monoclonal antibody tocilizumab (TCZ) has been …

Objective Elevated levels of pro-inflammatory cytokines are observed in severe COVID-19
infections, and cytokine storm is associated with disease severity. Tocilizumab, an …

Tocilizumab has been reported to attenuate the “cytokine storm” in COVID-19 patients. We
attempted to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and …